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Abstract
Background: Detailed molecular analyses of cells from rheumatoid arthritis (RA) synovium hold promise in identifying
cellular phenotypes that drive tissue pathology and joint damage. The Accelerating Medicines Partnership RA/SLE
Network aims to deconstruct autoimmune pathology by examining cells within target tissues through multiple high-
dimensional assays. Robust standardized protocols need to be developed before cellular phenotypes at a single cell
level can be effectively compared across patient samples.
Methods: Multiple clinical sites collected cryopreserved synovial tissue fragments from arthroplasty and synovial biopsy
in a 10% DMSO solution. Mechanical and enzymatic dissociation parameters were optimized for viable cell extraction
and surface protein preservation for cell sorting and mass cytometry, as well as for reproducibility in RNA sequencing
(RNA-seq). Cryopreserved synovial samples were collectively analyzed at a central processing site by a custom-designed
and validated 35-marker mass cytometry panel. In parallel, each sample was flow sorted into fibroblast, T-cell, B-cell,
and macrophage suspensions for bulk population RNA-seq and plate-based single-cell CEL-Seq2 RNA-seq.
Results: Upon dissociation, cryopreserved synovial tissue fragments yielded a high frequency of viable cells, comparable
to samples undergoing immediate processing. Optimization of synovial tissue dissociation across six clinical collection
sites with ~ 30 arthroplasty and ~ 20 biopsy samples yielded a consensus digestion protocol using 100 μg/ml of
Liberase™ TL enzyme preparation. This protocol yielded immune and stromal cell lineages with preserved surface markers
and minimized variability across replicate RNA-seq transcriptomes. Mass cytometry analysis of cells from cryopreserved
synovium distinguished diverse fibroblast phenotypes, distinct populations of memory B cells and antibody-secreting
cells, and multiple CD4+ and CD8+ T-cell activation states. Bulk RNA-seq of sorted cell populations demonstrated robust
separation of synovial lymphocytes, fibroblasts, and macrophages. Single-cell RNA-seq produced transcriptomes of over
1000 genes/cell, including transcripts encoding characteristic lineage markers identified.
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Conclusions: We have established a robust protocol to acquire viable cells from cryopreserved synovial tissue with intact
transcriptomes and cell surface phenotypes. A centralized pipeline to generate multiple high-dimensional analyses of
synovial tissue samples collected across a collaborative network was developed. Integrated analysis of such datasets from
large patient cohorts may help define molecular heterogeneity within RA pathology and identify new therapeutic targets
and biomarkers.
Keywords: Rheumatoid arthritis, Synovial tissue, Accelerating Medicines Partnership, RNA sequencing, CyTOF, Mass
cytometry, Arthroplasty, Synovial biopsy,
Background
The destructive inflammatory environment in rheuma-
toid arthritis (RA) synovium results from the activity of
various cell types, including synovial fibroblasts, macro-
phages, lymphocytes, osteoclasts, and vascular endothe-
lial cells [1–5]. Multiple pathways can be targeted to
treat RA, including inhibition of tumor necrosis factor
(TNF) or interleukin-6 (IL-6) signaling, blockade of
T-cell costimulation, depletion of B cells, and inhibition
of the JAK/STAT pathway [6]. However, despite the
advent of biologic therapies, up to ~ 2/3 of RA patients
do not achieve sustained disease remission [7], and there
are no reliable biomarkers that serve to guide selection
of specific therapeutic options for the individual patient.
A more comprehensive interrogation of cells present in
rheumatoid synovium may identify additional pathologic
pathways targetable by therapeutics and aid in stratifying
patients into disease subsets and treatment response
categories based on informative biomarkers [8, 9]. Such
studies have previously been limited by the lack of
methods to simultaneously recover and assay the diver-
sity of cell types in the synovium and by the challenge of
applying high-dimensional single cell analytics to suffi-
cient numbers of patient samples. In addition, compari-
sons of identical cell lineages isolated from targeted
tissues in patients with RA and other diseases such as
systemic lupus erythematosus (SLE) have not been
performed.
In recognition of these needs, the NIH Accelerating
Medicines Partnership (AMP) RA/SLE Network was
assembled with the goal of generating detailed analyses
of synovial tissue samples from a large number of RA
patients. The RA Working Group of the AMP RA/SLE
Network (or AMP RA network) has developed a pipeline
to study RA synovial tissue samples through parallel
high-dimensional analyses including mass cytometry,
bulk RNA-seq of selected cell populations, and single
cell RNA-seq. Mass cytometry can define the cellular
landscape of tissues, while RNA-seq delves deeper into
the gene expression profile for each cell type. When
performed at scale on a large patient cohort, these assays
have the potential to aid in developing personalized
therapeutic approaches for RA.
To amass an RA cohort of sufficient size, numerous
clinical collection sites contributed synovial tissue
samples. The network set out to develop a pipeline for
uniform and reproducible sample handling involving
cryopreservation of intact synovial tissue samples. The
frozen tissue fragments were then shipped to a central
processing site capable of performing multiple
high-dimensional analyses in parallel for each sample.
The protocol was optimized for two sources of tissue:
synovial biopsy obtained for research and clinically indi-
cated excision during arthroplasty.
Here, we report the AMP RA network protocol for
dissociation and analysis of immune and stromal cells from
cryopreserved synovial tissue by multiple high-dimensional
technologies. We describe a consensus protocol for synovial
tissue disaggregation that results in high yields of viable
cells with preserved surface marker expression—for both
larger arthroplasty and millimeter-sized biopsy samples.
We also describe an experimental pipeline to analyze each
sample in parallel using single-cell RNA-seq and low-input
bulk RNA-seq on selected populations, as well as mass
cytometry with defined markers for synovial cells. This
pipeline allows for cytometric identification and quantifica-
tion of numerous immune and stromal cell populations, as
well as robust transcriptomic analyses of small populations
of cells from pathologic synovial samples. These methods
are adaptable for use in multiple sites and have been
adopted and utilized by the AMP RA network.
Methods
Human patient samples
Patients with RA fulfilled the ACR 2010 Rheumatoid
Arthritis classification criteria or were identified by the
participating site rheumatologist as having clinical RA [6].
A diagnosis of osteoarthritis (OA) was defined by the
treating surgeon and confirmed by chart review. Synovial
tissue samples were acquired by two different methods:
arthroplasty and ultrasound-guided synovial biopsy.
Arthroplasty samples were acquired after removal as part
of standard of care at four US institutions (Hospital for
Special Surgery, NY; University California San Diego, CA;
University of Pittsburgh, PA; and University of Rochester,
NY). All synovial biopsy samples were acquired from
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clinically inflamed joints under research protocols at the
University of Birmingham, UK and Barts & the London
School of Medicine and Dentistry, UK. The study received
institutional review board approval at each site.
Arthroplasty synovial tissue collection
Synovial tissue excised as standard of care during arthro-
plasty was transported from the operating room to a
laboratory in ice-cold PBS. The tissue was identified as
synovium by characteristic features: a fibrous or elastic
tissue, pink or reddish in appearance. Small fragments
(~ 1–2 mm3) were generated by dissecting with forceps
or surgical scissors. Six fragments (~ 150 mg total)
across the tissue were randomly combined to make indi-
vidual aliquots [10, 11].
Synovial biopsy procedures
Synovial biopsy samples were obtained under ultrasound
guidance by an experienced interventionist using either a
needle biopsy or portal and forceps. For needle biopsy pro-
cedures, a 14G or 16G spring-loaded Cook Quick-Core® Bi-
opsy needle was used to obtain multiple fragments [12, 13].
For the portal-based approach, a portal (Merit Medical
Prelude 7F) was initially inserted into the synovial cavity
with multiple samples and then retrieved using flexible
2.0–2.2 mm forceps [14, 15]. Six biopsy fragments were
randomly allocated per aliquot.
Synovial tissue cryopreservation and thawing
Synovial tissues were either (1) disaggregated immediately
followed by cryopreservation of dissociated cells or (2) cut
into fragments that were cryopreserved for subsequent
disaggregation at a central processing site. Dissociated
synovial cells were resuspended in CryoStor® CS10 (Bio-
Life Solutions) at ~ 2 million cells/ml to viably freeze
them. Intact synovial tissue samples were divided into
fragments as already described and transferred to a cryo-
vial (1.5 ml; Nalgene) containing 1 ml of CryoStor® CS10
for viable freezing. Cryovials were then placed in an insu-
lated container with isopropanol in the bottom chamber
for slow freezing (Mr. Frosty; Nalgene), which comprised
incubation at 4 °C for 10 min followed by 1 day at − 80 °C.
The samples were then either shipped on dry ice or trans-
ferred into liquid nitrogen for long-term storage.
Synovial fragments were thawed by rapidly warming the
cryovial in a 37 °C water bath. The preservation media was
filtered out through a 70-μm strainer. The tissue was then
rinsed through a series of incubations in a six-well culture
plate: 10 min in 10% FBS/RPMI at room temperature with
intermittent swirling, a quick rinse in 10% FBS/RPMI, and
a final rinse in serum-free RPMI. Frozen synovial cells were
thawed rapidly in a 37 °C water bath and transferred into
20 ml of 10% FBS/RPMI, centrifuged to pellet cells, and
then resuspended in media for downstream analyses.
Dissociation of synovial tissue
Both arthroplasty and synovial biopsy samples were
dissociated by a combination of enzymatic digestion and
mechanical disruption with various test conditions de-
scribed in Results. The final consensus AMP RA net-
work enzyme digestion uses RPMI media with Liberase™
TL enzyme preparations (100 μg/ml; Roche) and DNase
I (100 μg/ml; Roche).
Arthroplasty tissue
To achieve consistent mechanical disruption and proteo-
lytic enzyme exposure across a fragment of tissue, large
synovial specimens (> 150 mg) were cut into small
fragments (~ 2 mm3) using surgical scissors. Mechanical
disruption of arthroplasty samples (six tissue fragments
totaling ≥ 500 mg) was carried out by a gentleMACS disso-
ciator system (Miltenyi) with the m_Spleen 04.01 setting,
which involves churning and shredding in a sterile dispos-
able tube. Enzymatic digestion was performed in RPMI
medium at 37 °C for 30 min. A large volume of 5% FBS/
RPMI was then added to terminate the enzymatic reaction.
The tissue was ground through a 70-μm filter using the flat
plastic end of a 3-ml syringe plunger to disperse the
remaining intact tissue and dispense dissociated cells.
Synovial biopsy tissue
For the samples obtained by synovial biopsy, tissue frag-
ments were minced into small fragments (~1 mm3) using
a scalpel. Samples were then subjected to enzymatic diges-
tion at 37 °C while being exposed to continuous stirring in
a U-bottom polystyrene tube (12 × 75 mm2) with a mag-
netic stir bar for 30 min. Halfway through the enzymatic
digestion, samples were passed gently through a 16G syr-
inge needle 10 times for additional mechanical disruption.
RNA extraction from whole synovial tissue fragments
For samples used in the aforementioned dissociation
protocol, synovial tissue fragments were also preserved for
whole tissue RNA extraction. Three whole tissue replicates
were collected for each sample, with six fragments placed
into a cryovial containing 1 ml of RNALater (Qiagen) and
inverted three times. The cryovials were incubated
overnight at 4 °C. The next day, the cryovials were spun at
~ 1000×g for 30 s and most of the RNALater was removed,
leaving only enough RNALater to cover the tissue. The
cryovials were then placed in storage at − 70 °C. For RNA
extraction, samples were thawed and fragments transferred
into RLT lysis buffer (Qiagen) + 1% β-mercaptoethanol
(Sigma) and homogenized using a TissueLyser II (Qiagen)
before RNA isolation using RNeasy columns.
Flow cytometry cell sorting
Synovial cell suspensions were stained with an 11-color
flow cytometry panel designed to identify synovial stromal
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and leukocyte populations. Antibodies included anti-CD
45-FITC (HI30), anti-CD90-PE(5E10), anti-podoplanin-
PerCP/eFluor710 (NZ1.3), anti-CD3-PECy7 (UCHT1),
anti-CD19-BV421 (HIB19), anti-CD14-BV510 (M5E2),
anti-CD34-BV605 (4H11), anti-CD4-BV650 (RPA-T4),
anti-CD8-BV711 (SK1), anti-CD31-AlexaFluor700 (WM59),
anti-CD27-APC (M-T271), anti-CD235a-APC/AF750, TruS-
tain FcX, and propidium iodide. Cells were stained in
HEPES-buffered saline (20 mM HEPES, 137 mM NaCl,
3 mM KCl, 1 mM CaCl2) with 1% bovine serum albumin
(BSA) for 30 min, then washed once, resuspended in the
same buffer with propidium iodide added, vortexed briefly,
and passed through a 100-μm filter.
Cells were sorted on a three-laser BD FACSAria Fusion
cell sorter. Intact cells were gated according to FSC-A and
SSC-A. Doublets were excluded by serial FSC-H/FSC-W
and SSC-H/SSC-W gates. Nonviable cells were excluded
based on propidium iodide uptake. Cells were sorted
through a 100-μm nozzle at 20 psi.
A serial sorting strategy was used to sequentially capture
cells for bulk RNA-seq and then single-cell RNA-seq if
sufficient numbers of cells were present. First, 1000 cells
of the targeted cell type were sorted for low-input
RNA-seq into a 1.7-ml Eppendorf tube containing 350 μl
of RLT lysis buffer (Qiagen) + 1% β-mercaptoethanol.
Once 1000 cells of a particular cell type were collected,
the sort was stopped and the tube was exchanged for a
second tube containing FACS buffer. Sorting was then re-
sumed and the rest of the cells of that type were collected
into the second tube as viable cells. This process was
carried out for four targeted populations. Live cells of each
population that were sorted into FACS buffer were then
resorted as single cells into wells of 384-well plates
containing 1 μl of 1% NP-40, targeting up to 144 cells of
each type per sample.
RNA sequencing on low-input bulk populations
RNA from sorted bulk cell populations was isolated using
RNeasy columns (Qiagen). RNA from up to 1000 cells
was treated with DNase I (New England Biolabs), and then
concentrated using Agencourt RNAClean XP beads
(Beckman Coulter). Full-length cDNA and sequencing
libraries were prepared using the Smart-Seq2 protocol as
described previously [16]. Libraries were sequenced on a
MiSeq (Illumina) to generate 25-base-pair, paired-end
reads totaling a fragment length of 50 base pairs.
Single-cell RNA sequencing
Single cell RNAseq (scRNA-Seq) was performed using the
CEL-Seq2 method [17] with the following modifications.
Single cells were sorted into 384-well plates containing
0.6 μl of 1% NP-40 buffer in each well. Then, 0.6 μl dNTPs
(10 mM each; NEB) and 5 nl of barcoded reverse
transcription primer (1 μg/μl) were added to each well
along with 20 nl of ERCC spike-in (diluted 1:800,000).
Reactions were incubated at 65 °C for 5 min, and then
moved immediately to ice. Reverse transcription reactions
were carried out as described previously [17] and cDNA
was purified using 0.8× volumes of AMPure XP beads
(Beckman Coulter). In-vitro transcription reactions (IVT)
were performed as described followed by EXO-SAP treat-
ment. Amplified RNA (aRNA) was fragmented at 80 °C
for 3 min and purified using RNAClean XP beads (Beck-
man Coulter). The purified aRNA was converted to cDNA
using an anchored random primer and Illumina adaptor
sequences were added by PCR. The final cDNA library
was purified using AMPure XP beads (Beckman Coulter).
Libraries were sequenced on a Hiseq 2500 (Illumina) in
Rapid Run Mode to generate paired-end reads. Forward
reads (35 nt) were mapped to human reference genome
hg19 using STAR v2.5 [18], while reverse reads (15 nt) in-
cluded cellular and molecular barcodes (6 nt each). Basic
analyses of single-cell RNA-seq data, including quantifica-
tion of genes detected per cell, filtering of cells with less
than 1000 detected genes, and principal components ana-
lyses, were performed using RSEM [19].
Differential expression
To examine differential gene expression profiles between
RA and OA synovial tissues processed through the consen-
sus disaggregation protocol, tissue samples were collected
from 10 RA patients and 10 OA patients. From these 20
patients, 2–8 replicates were generated per donor for a total
of 87 samples. We performed differential expression ana-
lysis by fitting a linear mixed model to each gene, in which
we controlled for unwanted technical variation with donor
and site as random effects.
Gene Ontology term enrichment analysis
We tested Gene Ontology (GO) enrichment with differen-
tially expressed genes. We used Ensembl gene IDs down-
loaded in April 2016, including 9797 GO terms and 15,693
genes. The minimal hypergeometric test was used to test
for significance [20].
Mass cytometry
Synovial cells were resuspended in PBS/1%BSA with
primary antibody cocktails at 1:100 dilution for 30 min
(Additional file 1: Table S1). All antibodies were obtained
from the Longwood Medical Area CyTOF Antibody
Resource Core (Boston, MA, USA). Cisplatin was added
at 1:400 dilution for the last 5 min of the stain to assess
viability. Cells were then washed and fixed in 1.6%
paraformaldehyde for 10 min at room temperature. Cells
were then washed and incubated with Ebioscience
Transcription Factor Fix/Perm Buffer for 30 min, washed
in Ebioscience perm buffer, and stained for intracellular
markers at 1:100 for 30 min. Cells were refixed in 1.6%
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paraformaldehyde for 10 min and stored overnight in
PBS/1%BSA. The following day, cells were incubated with
MaxPar Intercalator-Ir 500 μM 1:4000 in PBS for 20 min,
and then washed twice with MilliQ water, filtered, and an-
alyzed on a Helios instrument (Fluidigm). Mass cytometry
data were normalized using EQ™ Four Element Calibra-
tion Beads (Fluidigm) as described previously [21]. viSNE
analysis was performed using the Barnes-Hut SNE imple-
mentation on Cytobank (www.cytobank.org). Gated live
cells (DNA-positive, cisplatin-negative) were analyzed
using all available protein markers. Biaxial gating was per-
formed using FlowJo 10.0.7.
Results
Synovial tissue dissociation: optimizing cell yield and
surface marker preservation
Laboratories within the AMP RA network (Fig. 1a) ini-
tially set out to collectively establish a standard operating
procedure for isolating cells of differing lineages from
synovial tissue. This protocol required balancing rigorous
dissociation of stromal cells that adhere tightly to the
tissue matrix, while minimizing perturbations and main-
taining viability, RNA stability, and key surface proteins
required for downstream isolation and assays. In addition,
methods were needed to handle both large arthroplasty
samples and small synovial biopsy samples (Fig. 1b).
Selection of methods for mechanical disruption
Pilot experiments across several sites suggested that vari-
ous forms of mechanical disruption could be used,
including manual inversion of the tube or incubation in
a Stomacher® 400 circulator. Dissociation using the
gentleMACS was selected for arthroplasty as this
method provided an automated and standardized proto-
col that could be implemented across laboratories
(Fig. 1c). However, dissociation of small synovial biopsy
fragments (~ 0.5–1 mm3) using the gentleMACS system
generated variable and insufficient yields, possibly due to
cell retention in the dissociation container. Therefore,
synovial biopsy samples were subjected to mechanical
disruption by continuous magnetic stirring, combined
with trituration through a syringe needle.
Enzymatic dissociation combined with mechanical
disruption generates high cell yields
To test the impact of combining enzymatic treatment with
mechanical dissociation, proteolytic enzymes were added
to the media during mechanical dissociation. For the
majority of tissue samples, higher cell yields were obtained
when synovial fragments were incubated with enzyme in
addition to mechanical disruption (Fig. 2a). Importantly
for highly adherent stromal (PDPN+CD45–) lineages, the
proportion recovered increased with enzymatic digestion
(Fig. 2b, c).
Proteolytic enzyme preparations differ in surface marker
preservation
Focusing on highly purified enzyme formulations designed
for standardized protocols, the consortium tested Liber-
ase™ mixtures containing thermolysin (T) or dispase (D)
in combination with collagenase. As proteolytic enzymes
can cleave cell surface proteins [22, 23], we tested the
enzyme panel to identify a formulation that preserved
important cell surface proteins such as CD3 and CD4.
Certain formulations compromised the detection of cell
surface proteins. For example, on CD3+ T cells isolated
from synovium, a decline in CD4 surface detection was
observed with Liberase™ Dispase-High (DH),
Thermolysin-Medium (TM), and Thermolysin-High (TH)
compared to no enzyme treatment or Thermolysin-Low
(TL) and Dispase-Low (DL) (Fig. 2d). As peripheral blood
mononuclear cell preparations with equal numbers of
circulating T cells resulted in a similar pattern of loss in
CD4 detection when treated with the enzymes, the decline
in CD4 levels in the synovial preparations is likely due to
direct degradation of the cell surface protein by proteases
rather than a selective reduction in extracting CD4+ T
subsets (Additional file 1: Figure S1a). As Liberase™ TL
versus TM mixtures proved equally efficient at dissociat-
ing out both stromal and hematopoietic cells (Additional
file 1: Figure S1b), Liberase™ TL was chosen for both high
cell yields and preservation of cell surface markers for
downstream analyses, including mass cytometry.
Optimization of proteolytic enzyme concentrations
To determine the optimal concentration of proteolytic
enzyme for consistent cell recovery and reproducibility of
downstream assays, four network sites processed
arthroplasty samples using three different Liberase™ TL
concentrations, with three technical replicates for each con-
centration. In comparison to the 25 and 50 μg/ml concen-
trations, the 100 μg/ml concentration yielded the highest
amount of intact RNA after tissue dissociation (Fig. 2e). In
addition, synovial samples processed with 100 μg/ml
enzyme concentration demonstrated the lowest variance in
RNA-seq gene expression across replicate samples, visually
depicted in the principal component analysis (PCA) plots
where distance between replicates is minimized with the
100 μg/ml concentration (Fig. 2f). Next, we computed the
sum of squares within (SSW) to quantify replicate similar-
ities within each of the three enzyme concentrations. Here,
we also observed that replicates processed with 100 μg/ml
had the least variation (Fig. 2g).
To gain insight into the source of gene expression vari-
ation across synovial samples, we applied analysis of vari-
ance (ANOVA) to each principal component to assess the
contribution of the following sources: site, donor, and the
potential impact of the dissociation process (Additional
file 1: Figure S1c). The majority of gene expression
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variation associated with donor differences (PC1 and
PC2), which encompasses biological differences such as
disease state. Site-specific collection and/or processing
differences also contributed variation (PC1). Of note, the
AMP Network has designated a central processing site to
eliminate site-specific dissociation effects.
Sample variability in PC3 and PC6 also related to gene
expression differences that were identified in a separate
RNAseq analysis comparing whole versus dissociated
synovial preparations (Additional file 1: Figure S1c–e).
The analysis comparing dissociated versus whole tis-
sue RNAseq was intended to identify dissociation-induced
effects, but involved mixtures of various cell types and,
correspondingly, much of the gene expression differences
indicated cell composition differences. These differences
likely relate to differences in the preparation protocols; for
example, adipocytes escape during spinning and aspiration
steps in the dissociation protocol, while red blood cells
may inadvertently be removed in whole tissue prepara-
tions during a salt solution incubation and subsequent as-
piration. Nonetheless, outside of cell type-specific genes,
there was an increase in stress response genes in dissoci-
ated cell preparations, similar to a previous report on
dissociation-induced effects in single cells [24]. This in-
cluded an upregulation in heat shock protein genes
(HSP1A1, HSP6A, HSP90AA) and early response genes
mass cytometry
(CyTOF)
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T cells
B cells
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T cells
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c
Fig. 1 AMP consortium pipeline for high-dimensional synovial tissue assays. a Numerous Clinical Collection Sites contributed cryopreserved synovial
samples to the Central Processing Site. b At the Clinical Collection Sites, synovial tissue was excised during research-oriented biopsies or routine
removal in arthroplasty surgeries. Tissues and dissociated synovial cells cryopreserved for centralized processing. c Synovial tissue mechanically
disaggregated via magnetic bar stirring in heated water bath for smaller biopsy fragments or gentleMACS dissociation for larger arthroplasty
specimens. Tissue dissociation also involved incubation with protein and nucleic acid degrading enzymes at 37 °C. After filtration of debris, sample
aliquots processed in parallel for mass cytometry (CyTOF) analysis and FACS-based sorting of four cell types for single-cell and bulk RNA sequencing
(RNA-seq). AMP Accelerating Medicines Partnership
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(FOS, JUN, ATF3) (Additional file 1: Figure S1d, e). Thus,
synovial cells demonstrating specific upregulation in this
signature could indicate a dissociation-induced gene expres-
sion pattern rather than a cell subset-specific program. For
subsequent single-cell RNAseq studies, individual synovial
cells with high levels of this stress response could either be
removed from the analyses or the signature could be ad-
justed for computationally.
Overall, these results suggest that dissociation with
100 μg/ml Liberase™ TL produces consistent and robust
recovery of diverse synovial stromal and immune cell
populations with the largest source of variation in the
samples due to donor biological differences.
Development of cryopreservation methods
Having established synovial dissociation methods, we then
focused on establishing a strategy to analyze samples ac-
quired at distant sites through a uniform high-dimensional
analysis pipeline. We first evaluated the feasibility of study-
ing synovial cells cryopreserved after tissue dissociation.
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computed after leave-one-out strategy where replicates from one donor are left out and SSW is computed with remaining samples. Student’s t
test used to test whether bootstrapped SSW values differ significantly. DH Dispase-High, DL Dispase-Low, PC principal component, PDPN
podoplanin, TH Thermolysin-High, TL Thermolysin-Low, TM Thermolysin-Medium
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From three different arthroplasty samples analyzed either
immediately after dissociation (fresh) or after freezing the
cells in a cryopreservation solution for at least 1 day,
comparable cell frequencies were extracted for synovial
fibroblasts, monocytes, T cells, and B cells (Fig. 3a). This
result, although based on only three samples, suggested that
synovial cells generally survive cryopreservation well, con-
sistent with prior studies [5, 25, 26].
In addition to cryopreserving dissociated synovial cells,
we next evaluated the feasibility of cryopreserving intact
synovial tissue fragments prior to dissociation. Notably,
three synovial biopsy tissues processed after cryopreser-
vation yielded cells with comparable viability to paired
tissue analyzed immediately after isolation (Fig. 3b). In
addition, flow cytometric analysis of cells from cryopre-
served synovial tissue showed robust detection of stro-
mal and hematopoietic cell populations, similar to fresh
synovial tissue (Fig. 3c). These results indicate that intact
synovial tissue can be cryopreserved for subsequent cel-
lular analyses.
We next examined whether application of the protocol
implementing 100 μg/ml of Liberase™ TL, mechanical
disaggregation, and viable freezing could detect robust ex-
pression pattern differences between dissociated synovial
cells from tissues from patients with RA and osteoarthritis
(OA). Importantly, an RNA-seq analysis of disaggregated
total synovial cells demonstrated an upregulation in RA of
genes involved in immune processes, such as immuno-
globulin binding, cellular response to molecules of bacter-
ial origin, leukocyte chemotaxis and migration, cytokine
production, and antigen processing and presentation by
MHC class II (Fig. 3d).
High-dimensional assays of synovial cells
A goal of the AMP Network is to generate both mass
cytometry and RNA-seq analyses of cells from cryopre-
served synovial samples dissociated by the protocol
described earlier. Acquisition of data for both of these
technologies from the same synovial sample allows the
coupling of detailed quantification of cell populations
with genome-wide transcriptomic analyses. These
combined analyses enable interrogation of correlations
between cell populations and transcriptomic signatures
with unprecedented resolution for a human autoimmune
disease tissue target. Because synovial samples vary
widely in both cell yield and composition, we developed
an algorithm to allocate cells for different analyses in a
step-wise fashion without prior knowledge of the cell
composition (Fig. 1c). Preliminary experiments indicated
that reproducible mass cytometry analyses could be
obtained from 100,000 synovial cells; therefore, for
samples that yielded over 200,000 synovial cells, approxi-
mately half of the cells were allocated to mass cytometry,
with the rest were used for sequential low-input and
single-cell RNA-seq analyses. When less than 200,000
synovial cells were obtained, mass cytometric analysis was
omitted and only RNA-seq analyses were performed.
Mass cytometry of synovial cells
A 35-parameter mass cytometry panel was developed to
identify stromal, vascular, and immune cells within syn-
ovial samples (Fig. 4a). Visualization of the mass cytome-
try data obtained from a cryopreserved synovial biopsy
sample using the dimensional reduction tool viSNE [27]
revealed clear discrimination of synovial fibroblasts (cad-
herin-11+), endothelial cells (VE-cadherin+), and immune
cell subsets from cryopreserved RA synovial tissue
(Fig. 4b). viSNE visualization highlighted the heterogeneity
within immune cell populations, which was confirmed by
biaxial gating. For example, two populations of B cells
were easily resolved, including one CD19+CD20+ popula-
tion and a distinct CD19+CD20–CD38hi population com-
prised of antibody-secreting cells (Fig. 4b, c) [28, 29].
Marked heterogeneity within the CD3+ T-cell population
was also evident, with multiple lobes of T cells visualized,
including a subset of PD-1hiICOS+CD4+ T cells (Fig. 4b, c)
[5]. This visualization also demonstrated heterogeneity
among the podoplanin+ synovial fibroblasts, including
fibroblast subpopulations that express CD90 and/or CD34
[25, 26]. These results indicate that high-resolution mass
cytometry data can be obtained from synovial cells
collected from cryopreserved intact synovial tissue that is
subsequently thawed and dissociated.
RNA-seq transcriptomics of synovial cell populations and
single cells
In addition to mass cytometry analyses, a major goal of
the AMP Network is to define molecular signatures and
pathways of disease by transcriptome analysis. Low-input
RNA-seq provided robust gene expression values for a
large number of protein coding genes averaged across
approximately 1000 cells. The complementary single-cell
RNA-seq approach provided a high-resolution view of the
heterogeneity of expression profiles between individual
cells. We designed a cell sorting workflow that prioritized
collecting cells for low-input RNA-seq, with a goal of col-
lecting 1000 cells from each of the four targeted cell types.
If more than 1000 cells of a targeted cell type were avail-
able, the remaining cells were sorted into a second collec-
tion tube for subsequent single-cell RNA-seq analysis
(Fig. 1c). This sorting scheme enabled capture of virtually
all of the cells for each of the four target populations for
low-input and single-cell RNA-seq.
Synovial cells were stained with a multidimensional flow
cytometry panel that could identify diverse cell populations
including fibroblasts (CD45–podoplanin+CD31−),
endothelial cells (CD45−podoplanin−CD31+), macrophages
(CD45+CD14+CD3−), and T cells (CD45+CD14−CD3+)
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(Fig. 5a). Low-input RNA-seq analysis of fibroblasts, macro-
phages, endothelial cells, and T cells sorted from three
cryopreserved RA synovial biopsy samples yielded tran-
scriptomes with 8000–13,000 genes detected from cell in-
puts ranging from 1000 cells down to 83 cells (Fig. 5a, b).
Principal components analysis robustly distinguished the
different cell types at the global transcriptomic level
(Fig. 5c). These results indicate that cells obtained from
cryopreserved biopsies yield transcriptomes that reflect the
expected cell identity.
Transcriptomes of single cells sorted from cryopre-
served RA synovium were obtained by RNA-seq through
the CEL-Seq2 platform. High-quality transcriptomes from
both single-cell fibroblasts and leukocytes from RA syno-
vium were generated, with fibroblasts generally yielding
higher gene counts (Fig. 6a). Principal components ana-
lysis of single cells from an RA synovial sample separated
the fibroblasts from the immune cells along PC1, and
mostly separated macrophages from T and B lymphocytes
along PC2 (Fig. 6b). Importantly, single cells from each
sorted cell population expressed markers expected for that
cell type. For example, the podoplanin transcript was
expressed primarily in fibroblasts, consistent with flow
cytometry and mass cytometry data, while the CD14 tran-
script was identified in sorted macrophages, an expected
finding since the cells were flow sorted by CD14 protein
expression (Fig. 6c). Similarly, the CD3E transcript was
uniquely detected in sorted T cells, while CD79A expres-
sion was unique to sorted B cells. These results indicate
that high-quality transcriptomes can be generated from
bulk populations and single cells obtained from cryopre-
served RA synovial tissue samples.
Discussion
Here we describe the development of an experimental
pipeline to analyze synovial tissue with multiple
high-dimensional technologies, aimed at deconstructing
the cellular and molecular features of RA. This standard-
ized and validated strategy enables single-cell analytics
on large sample numbers collected from numerous
clinical sites.
The integration of contemporary high-dimensional
assays provides the opportunity to dissect the properties
of tissues affected by rheumatic disease with a resolution
not previously possible. Histologic and immunohisto-
chemical assessments of synovium have revealed marked
heterogeneity in RA synovial pathology [13, 30]. Gene ex-
pression analyses of synovium by microarray have added
gene expression signatures to these histologic patterns
[31–34]. However, broad analyses of gene expression in
synovium have thus far been limited mainly to assess-
ments of whole tissue, which cannot distinguish which cell
types express the relevant genes [31, 35–38]. The analysis
pipeline described here enables simultaneous quantifica-
tion of a wide range of stromal and leukocyte subpopula-
tions by mass cytometry, paired with genome-wide
transcriptional analyses, both of targeted cell populations
and of single cells. Mass cytometry alone provides a
powerful, broad assessment of the cell types and
phenotypes within the tissue on a relatively large number
of cells [5]. Transcriptomic analyses of sorted subpopula-
tions can identify the cell types contributing specific gene
expression signatures derived in the synovium, including
signatures specific to RA synovium. Single-cell tran-
scriptomics allow a high-powered characterization of the
heterogeneity of cells across a tissue [39] and within cell
subsets that were previously classified as the same cell
type [25, 26, 40]. We propose that integrating the multiple
high-dimensional datasets acquired with this pipeline will
reveal how distinct cell types relate to specific aspects of
RA pathology. Applied to a large patient cohort, these
analyses have the potential to reveal functional pathologic
markers that distinguish patients with distinct clinical
trajectories and therapeutic responses [5].
Implementing these technologies requires robust tissue
processing protocols. The validation studies described
here, which were carried out by a collaboration among
laboratories with expertise in synovial tissue and RA,
provide a widely applicable, reproducible method for
obtaining single cells from RA synovium that performs
well in cytometric and transcriptomic analyses. Classically,
synovial tissue has been disaggregated by crude collage-
nase preparations, which often cleave cell surface proteins
and may contain bacterial products that stimulate im-
mune cells. Here, varied concentrations of highly purified
proteolytic enzyme preparations were assessed for preser-
vation of vulnerable cell surface proteins required for
downstream assays, as well as cell viability, RNA integrity,
and applicability to next-generation sequencing. Combin-
ing limited enzyme incubation time with mechanical dis-
aggregation yielded viable cell populations from disparate
lineages that performed well in downstream assays. It is
(See figure on previous page.)
Fig. 3 Cryopreservation of synovial fragments retains stromal and hematopoietic cell viability and RA synovial gene expression patterns. a
Frequency of synovial cell subpopulations from arthroplasty samples dissociated from freshly isolated or cryopreserved aliquots. b Cell viability
frequency assayed by flow cytometry for synovial biopsy samples dissociated from fresh or cryopreserved tissue fragments. c Flow cytometry
analysis of cells dissociated from synovial tissue either immediately or after cryopreservation. d Top 20 GO terms enriched for genes upregulated
in RA patient disaggregated synovial cells in comparison to patients with OA. N = 10 RA and 10 OA samples with 2–8 replicates per donor. ns no
significant difference, OA osteoarthritis, RA rheumatoid arthritis
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important to recognize that dissociating tissues into cell
suspensions may introduce processing signatures [24].
However, differences in transcriptome between intact and
dissociated tissue may arise from a number of sources.
These may include better representation of genes from
cells difficult to extract in the intact tissue samples, in
addition to potentially adverse consequences such as a
cellular response to tissue manipulation. Importantly, with
the synovial tissue disaggregation protocols developed
here, mass cytometry of the single cells obtained clearly
identified multiple expected cell populations in striking
detail. RNA-seq transcriptomic analyses also robustly
distinguished cells of different types at both the low-input
and single-cell level. Further, transcriptomic analysis of
synovial cells identified RA-specific gene signatures even
in the relatively small sample set presented with the
largest source of variation in the transcriptome due to
donor biological differences. While dissociation-induced
gene signatures are identifiable, they can be adjusted for
computationally if necessary. Taken together, these obser-
vations strongly argue for the potential of this approach to
discover new aspects of RA cellular pathology, which can
be further validated in intact tissues.
The ability to effectively cryopreserve synovial tissue
marks a major technical advance for synovial research.
The viability and flow cytometric phenotypes of cells from
cryopreserved synovial tissue samples were comparable to
those from freshly processed tissues. Cells obtained from
cryopreserved tissue samples were largely viable and
readily used for all of the mass cytometric and RNA-seq
analyses presented in this report. Cryopreservation of
intact synovial tissue provides a simple, rapid technique to
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preserve and transport affected tissues for cellular studies
in a multisite consortium. Tissue fragment cryopreserva-
tion enables sample collection from numerous clinical
sites, including those lacking the resources for tissue
dissociation. This approach also eliminates site-specific
processing effects, allowing samples to be processed at a
central site that possesses multiple high-dimensional
technologies, and to utilize batch processing of samples to
minimize technical variation and confounding effects.
While it remains to be determined how long cryopre-
served synovial tissue can be stored, samples have
been routinely stored in liquid nitrogen for several
months, and a small number of samples have been
analyzed over 1 year after freezing without obvious
decreases in cell yield.
In an ongoing phase I study, the AMP RA Network has
implemented this synovial tissue pipeline to study cryo-
preserved synovial samples from a pilot cohort of over 40
RA and OA patients with the goal of defining RA
disease-specific cellular populations and pathways. Greater
than half of the synovial samples processed yielded suffi-
cient cells for both mass cytometry and RNA-seq analyses,
with cell viabilities comparable to those reported here.
Analysis of cells from these phase I samples is in progress.
The phase I pilot study will be followed by a phase II
study involving a much larger cohort of RA patients,
including those with early disease, with a focus on identi-
fying RA tissue biomarkers and novel tissue drug targets.
A similar strategy of tissue cryopreservation has been
adopted by the AMP for single-cell transcriptomic
analyses of kidney biopsy samples from patients with
lupus nephritis, including development of a dissociation
protocol optimized for human kidney tissue [41]. Al-
though different tissues and cellular subsets may respond
to cryopreservation differently, the strategy of analyzing
cells from cryopreserved tissue appears readily adaptable
to multicenter studies of tissues in other inflammatory
diseases.
Conclusions
These studies demonstrate the feasibility and potential of
analyzing viable cells from cryopreserved synovial tissue
samples by multiple, complementary high-dimensional
analyses. Using an optimized dissociation protocol that
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provides high yields of viable cells with preserved cell sur-
face and transcriptomic features, synovial tissue samples
acquired across a multisite network can be analyzed in a
uniform way in order to identify dominant cell types and
pathways, as well as to characterize previously unidentified
cellular heterogeneity. Such approaches applied to large
numbers of patients offer new opportunities to discover
rheumatic disease biomarkers, targets for drug develop-
ment, and molecular stratification of synovial pathology.
Additional file
Additional file 1: Table S1. Mass cytometry panel for analysis of
synovial cells. Figure S1. Additional variables in synovial tissue enzymatic
treatment (PDF 2239 kb)
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